Strategy | Phase | Reference | ||
---|---|---|---|---|
Enhancing selectivity of CAR | Selecting safer antigen | Tumor-specific antigen | Clinical trial | [19] |
Aberrantly glycosylated antigens | Preclinical research | [57] | ||
TCR-like CAR | Preclinical research | |||
Combinatorial antigen targeting | Complementary signaling | Preclinical research | ||
SynNotch/CAR circulation | Preclinical research | [68] | ||
iCAR | Preclinical research | [70] | ||
Turning sensitivity of scFv | Turning the affinity | Preclinical research | ||
Masked CAR | Â | Preclinical research | [78] | |
Control CAR-T cell activity | Limiting CAR expression | Transient mRNA CAR | Clinical trial | |
Switchable CAR-T cell | Dimerizing small molecules | Preclinical research | ||
Tumor targeting antibody | Preclinical research | |||
Suicide gene | iCasp9 | Clinical trial | [92] | |
Antibody-mediated depletion | Clinical trial |